

Accepted Manuscript

Title: Effectiveness of physiotherapy for seniors with recurrent headaches associated with neck pain and dysfunction: a randomized controlled trial

Author: Sureeporn Uthaikhup, Jenjira Assapun, Kanokwan Watcharasaksilp, Gwendolen Jull

PII: S1529-9430(16)30849-X
DOI: <http://dx.doi.org/doi: 10.1016/j.spinee.2016.08.008>
Reference: SPINEE 57124

To appear in: *The Spine Journal*

Received date: 11-3-2016
Revised date: 3-6-2016
Accepted date: 2-8-2016



Please cite this article as: Sureeporn Uthaikhup, Jenjira Assapun, Kanokwan Watcharasaksilp, Gwendolen Jull, Effectiveness of physiotherapy for seniors with recurrent headaches associated with neck pain and dysfunction: a randomized controlled trial, *The Spine Journal* (2016), <http://dx.doi.org/doi: 10.1016/j.spinee.2016.08.008>.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Effectiveness of physiotherapy for seniors with recurrent headaches associated with neck pain and dysfunction: a randomized controlled trial

Sureeporn Uthaihpun^{1,2}, Jenjira Assapun¹, [Kanokwan Watcharasaksilp³](#), [Gwendolen Jull⁴](#)

¹ Department of Physical Therapy, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai, Thailand

² Research Center in Back, Neck and Other Joint Pain and Human Performance, Khon Kaen University, Khon Kaen, Thailand

³ Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

⁴ Physiotherapy, School of Health and Rehabilitation Sciences, The University of Queensland, Brisbane, Australia

Address for Correspondence

Dr Sureeporn Uthaihpun

Department of Physical Therapy

Faculty of Associated Medical Sciences

Chiang Mai University

Chiang Mai

Thailand, 50200

Ph: 66 53 949 249

Fax: 66 53 946 042

Email: sureeporn.uthaihpun@cmu.ac.th

Acknowledgements

1 This trial was granted by the Thailand Research Fund (TRF), grant number: 5580145.

2

3 **ABSTRACT**

4 **BACKGROUND CONTEXT:** A previous study demonstrated that in seniors, the presence of
5 cervical musculoskeletal impairment was not specific to cervicogenic headache but was present
6 in various recurrent headache types. Physiotherapy treatment is indicated in those seniors
7 diagnosed with cervicogenic headache but could also be adjunct treatment for those with
8 cervical musculoskeletal signs who are suspected of having transitional headaches.

9 **PURPOSE:** To determine the effectiveness of a physiotherapy program for seniors with
10 recurrent headaches associated with neck pain and cervical musculoskeletal dysfunction,
11 irrespective of the headache classification.

12 **STUDY DESIGN:** Prospective, stratified, randomized controlled trial with blinded outcome
13 assessment.

14 **PATIENT SAMPLE:** Sixty-five participants with recurrent headache, aged 50-75 years were
15 randomly assigned to either a physiotherapy (n =33) or usual care group (n = 32).

16 **OUTCOME MEASURES:** The primary outcome was headache frequency. Secondary
17 outcomes were headache intensity and duration, neck pain and disability, cervical range of
18 motion, quality of life, participant satisfaction and medication intake.

19 **METHODS:** Participants in the physiotherapy group received 14 treatment sessions.
20 Participants in the usual care group continued with their usual care. Outcome measures were
21 recorded at baseline, 11 weeks, 6 months and 9 months. This study was funded by a
22 government research fund of \$6850. No conflict of interest is declared.

23 **RESULTS:** There was no loss to follow-up for the primary outcome measure. Compared to
24 usual care, participants receiving physiotherapy reported significant reductions in headache
25 frequency immediately after treatment (mean difference -1.6 days, 95% CI -2.5 to -0.6), at the

1 6-month follow-up (-1.7 days, 95% CI -2.6 to -0.8), at the 9-month follow-up (-2.4 days, 95%
2 CI -3.2 to -1.5) and significant improvements in all secondary outcomes immediately post-
3 treatment and at the 6- and 9-month follow-ups, ($p < 0.05$ for all). No adverse events were
4 reported.

5 **CONCLUSION:** Physiotherapy treatment provided benefits over usual care for seniors with
6 recurrent headache associated with neck pain and dysfunction.

7

8 **KEY WORDS:** cervical disorder, headache, neck pain, physiotherapy, seniors

9

10

Accepted Manuscript

1 **Introduction**

2 Headache is a common health problem that affects quality of life. Headaches change with age
3 [1-3]. Their features become less typical, for example, a diagnosis of probable migraine is
4 more prevalent in seniors than migraine [4]. Secondary headaches increase in frequency [5]
5 and associated neck pain is common [2]. In line with this occurrence, we demonstrated that
6 cervical musculoskeletal dysfunction (CMD) was more prevalent in seniors with, than without
7 headache. CMD was not specific to cervicogenic headache but was present in various recurrent
8 headache types (e.g. migraine, tension-type headache) [6]. Nevertheless, the degree of CMD
9 was variable. We characterised it as greater or lesser based principally on loss of motion and
10 pain on palpation of cervical joints. We found that greater or lesser dysfunction likewise was
11 not related to headache classification or length of headache history, albeit that there was a trend
12 for more cervicogenic headaches to be in the group with greater neck dysfunction. The CMD
13 and neck pain in seniors might be the source of headache (cervicogenic headache), or a
14 prevalent co-morbid feature and possibly an additional peripheral source of nociception in
15 primary headaches as part of their changing nature with ageing.

16
17 Changes in the nature of headache with age play an important role in the choice of treatment.
18 The effective management of headache in seniors remains a challenge. There is evidence that
19 physiotherapy methods are effective for treating the CMD of cervicogenic headache [7, 8]. It is
20 unknown if management of the neck could be a useful adjunct treatment for those seniors with
21 other recurrent headaches as probable migraine when they are associated with neck pain and
22 CMD. This is a safe option given the widespread concerns about medication overuse, adverse
23 drug events and drug interactions in senior populations [9, 10]. Management of CMD may
24 reduce headache frequency or severity, enhance the quality of life, and lessen medication use,
25 cost and adverse drug events.

1

2 This trial was undertaken to determine the effectiveness of a physiotherapy program of cervical
3 mobilization and therapeutic exercise for seniors with recurrent headache irrespective of
4 headache classification, provided there was associated with neck pain and CMD. We
5 hypothesized that treatment of the neck disorder would be more effective in reducing headache
6 frequency than usual care and as secondary outcomes, would result in greater improvements in
7 headache duration and intensity, cervical range of motion, neck pain and disability, medication
8 use, quality of life and participant's perception of treatment benefit. If treatment of the neck
9 proved effective, we planned subgroup analyses to determine if there was a difference in effect
10 if the headache was diagnosed as cervicogenic or whether greater or lesser musculoskeletal
11 dysfunction was judged to be present.

12

13 **Methods**

14 **Study design**

15 A prospective, assessor-blinded, parallel group (1:1 allocation ratio) randomized controlled
16 trial. Ethical approval was gained from the ethical review committee for research in humans,
17 Faculty of Medicine, Chiang Mai University (#349/2012). The study was conducted in
18 accordance with the Declaration of Helsinki. All participants provided written informed
19 consent. (ClinicalTrial.gov NCT01736774).

20

21 **Participants**

22 Participants were recruited both from the headache clinic at Maharaj University Hospital and
23 from the local community by advertising on local radio, in newspapers and flyers. A
24 neurologist from the headache clinic screened and diagnosed potential participants from both
25 sources. To be eligible for the study, participants were to be aged between 50-75 years, have

1 recurrent headaches diagnosed as either migraine, tension-type, cervicogenic or mixed
2 headache with associated neck pain and CMD (restriction in active range of cervical motion in
3 extension and rotation and palpable upper cervical joint dysfunction) [6]. Headache frequency
4 had to be at least one per week over the past year, neck ≥ 3 on a 0-10 visual analogue scale
5 (VAS) and neck disability ≥ 10 out of 100 as measured by the Neck Disability Index (NDI).
6 Exclusion criteria were: headache diagnosed as temporal arteritis, trigeminal neuralgia, cluster
7 headache, chronic paroxysmal hemicrania/hemicranias continua; temporomandibular disorders;
8 neurological disorders (e.g. Parkinson disease, stroke); cognitive disturbance; previous serious
9 head and neck trauma; any condition that contraindicated cervical mobilization; or receipt of
10 physiotherapy treatment for headache during the past 12 months.

11
12 A research assistant conducted a preliminary screening telephone interview with participants
13 responding to advertisements. For those provisionally eligible for the trial, appointments were
14 made with the trial neurologist and an experienced physiotherapist. The neurologist examined
15 all potential participants (recruited from advertisements or the headache clinic) and assigned a
16 headache diagnosis (migraine, tension-type, cervicogenic, mixed headache or other headache
17 type) according to the criteria of the International Headache Society (IHS) [11] or for
18 cervicogenic headache, the criteria of the Cervicogenic Headache International Study Group
19 [12]. The physiotherapist, blinded to the neurologist's diagnosis, performed a physical
20 examination of the neck to identify the presence or not of CMD and make the clinical rating of
21 greater, lesser or no CMD [6]. This included assessment of range of movement and a manual
22 examination of the cervical segments [13, 14]. The participants rated any pain provoked on
23 palpation on a numerical rating scale (NRS) and the physiotherapist rated the perceived tissue
24 resistance to the manual palpation as normal, slight, moderate, or marked resistance. A joint
25 was classified as symptomatic if pain provoked by manual examination was $>2/10$ in

1 combination with the physiotherapist's rating of moderately or markedly abnormal tissue
2 compliance [15]. A participant was judged to have greater CMD if they had at least 2 levels of
3 symptomatic joint dysfunction and displayed restricted range of cervical motion in extension
4 and rotation. If musculoskeletal dysfunction was present, but rated to lesser degree, the
5 participant was assigned to lesser CMD. If manual examination and range of movement were
6 painfree, a participant was assigned to have no CMD. On the basis of the neurologist's and
7 physiotherapist's assessments, participants were either invited to participate or were judged
8 ineligible.

9

10 **Randomization and masking**

11 Randomization was undertaken by an independent research assistant, not otherwise involved in
12 the trial. Randomization was by computer generated permuted blocks with a block size of four,
13 stratified by greater or lesser CMD, to ensure similar dysfunction between groups. Allocation
14 was concealed in sequentially numbered, sealed, opaque envelopes. The envelopes were
15 opened by the research assistant allocating patients to the respective intervention.
16 Physiotherapists were not blinded to the treatment being provided but were blinded to
17 participants' headache diagnosis. Blinded assessors collected all baseline and follow-up
18 physical measures and entered questionnaire data.

19

20 **Interventions**

21 Physiotherapy: The intervention was delivered by two physiotherapists, experienced in the trial
22 treatments. The treatment period was 10-weeks and commenced within one week of baseline
23 assessment. Participants received 14 individual treatment sessions (2 visits per week for the
24 first 4 weeks followed by one visit per week for the last 6 weeks). Each treatment session
25 lasted approximately 45 minutes and included a combination of cervical mobilization and a

1 therapeutic exercise program, a regime which has proven successful in previous trials of
2 headache management [7, 16]. The cervical mobilization consisted of low-velocity techniques
3 [17]. The therapeutic exercise program was a low load exercise for the craniocervical flexor [7,
4 18] and axioscapular muscles [19] and postural correction exercises [18, 20]. Muscle
5 lengthening exercise could also be given to address any muscle tightness. The elements of the
6 treatment were delivered at the discretion of the physiotherapist, based on the initial and
7 progressive assessment of participant's cervical joint and muscular dysfunction. The exercise
8 programs were progressed gradually from non-functional to functional performance.
9 Participants were instructed to practice their exercise once daily (10-20 minutes) during the
10 intervention period, without aggravating pain. Participants completed an exercise diary to
11 monitor compliance and record adverse events. Significant adverse effects were defined as any
12 increases in pain (headache or neck pain), loss of neck motion, and/or loss of function as a
13 result of the intervention.

14
15 Usual care: Participants randomly allocated to the usual care group were asked to continue
16 with their medication and were able to receive other care as they thought appropriate except for
17 physiotherapy treatment. To avoid the risks of behavioral change, the usual care group received
18 only neutral information. No extra information about their condition or treatment advice was
19 provided. Any treatments received and adverse events during the 10 week intervention period
20 were recorded in a diary log-book.

21 22 **Measurements**

23 A baseline questionnaire was administered to document participant demographics, headache
24 history and any treatment received to date. A daily headache diary was used to record headache
25 measures (frequency, intensity and duration) one week before baseline and follow-up

1 assessments. Primary and secondary outcome measures were recorded at baseline, 11 weeks, 6
2 months and 9 months after randomization. The exception was cervical range of motion,
3 participants' perception of treatment benefit and quality of life which were measured at
4 baseline, 11 weeks and 9 months.

5

6 ***Primary outcome measure***

7 Headache frequency was the primary outcome measure [21]. The number of headache days
8 was recorded in a daily headache diary one week before the respective assessment dates and
9 the total number of headache days per week was used for analysis.

10

11 ***Secondary outcome measures***

12 *Other headache measures:* Headache intensity and duration were measured with a daily
13 headache diary. Participants reported daily headache pain intensity using a 0-10 NRS and the
14 number of hours of headache for each day in the past week. Means scores across the 7-day
15 period were used for analysis.

16

17 *Neck pain and disability measures:* Neck pain intensity was measured using a VAS. The
18 participants indicated their average neck pain intensity over the past week by marking a
19 100mm line. Likewise a weekly measure was recorded of neck related disability using the
20 Neck Disability Index-Thai version (NDI-TH) [22]. The NDI-TH has 10 sections and each has
21 a five point Likert response (total score, 50). A higher score indicates greater perceived
22 disability [23].

23

24 *Cervical range of motion:* A cervical range of motion (CROM) device was used to measure
25 flexion/extension, left-right rotation, left-right lateral flexion and left-right upper cervical
26 rotation [24]. The CROM is a reliable tool to assess cervical range of motion [25].

1

2 *Quality of life:* Health-related quality of life was assessed using the SF-36-Thai version [26],
3 which contains 36 questions covering eight domains of health. The eight domains were
4 summed into a physical component summary score (PCS) and a mental component summary
5 score (MCS) and then expressed as a percentage, with higher score representing better health.

6

7 *Participant's perception of treatment benefit:* Perceived benefit was measured with a 0-10
8 scale (0 = no benefit and 10 = maximum benefit).

9

10 *Medication:* Participants recorded the type and dose of all medications taken in a medication
11 diary for a one-week baseline period and for one week prior to follow-up points. Medication
12 consumption was converted into defined daily dose (DDD) unit by multiplying the units
13 dispensed field with the DDD conversion [27]. For example, the DDD for paracetamol is 3g
14 and the strength of one tablet is 500mg. Each 500mg tablet is equivalent to 0.17 DDD.
15 Multiplying the quantity (6 tablets) by a conversion factor of 0.17 equals a consumption of
16 1.02 DDDs. The sum of DDDs of all medications consumed in one week was calculated and
17 used for analysis.

18

19 **Procedure**

20 Participants attended the Department of Physiotherapy, Chiang Mai University for baseline
21 assessment. They were randomly allocated to either the 10 week physiotherapy program or
22 usual care. All participants were reassessed at 11 weeks (at the university), 6 months (postal
23 questionnaires) and 9 months (at the university). All participants were asked to complete a
24 daily headache diary for the week before each re-assessment date. They noted the presence or
25 not of headache on each day, its intensity and duration and also whether it was their familiar
26 headache or a different headache, for example, associated with a cold or flu. Participants

1 receiving the physiotherapy intervention were asked to refrain from seeking other treatment for
2 their headache during the trial. Due to ethical considerations, usual medication was not
3 withheld from any participant, regardless of group. Participants recorded the type and dose of
4 all medications taken in a medication diary. Reminder telephone calls were used to help to
5 maintain a high retention rate, including two calls to participants in the usual care group during
6 the 10 week intervention.

7

8 **Sample size calculation**

9 Sample size was based on the primary outcome of headache days per week. According to the
10 IHS guidelines [21], a 50% reduction in headache days per week is considered a clinically
11 significant difference. A sample size of 58 participants was required for the study based on a
12 priori power analysis with a power of 0.8 and an alpha of 0.05. Assuming a dropout rate of
13 10%, 64 participants (32 per group) was the target sample size for enrollment.

14

15 **Statistical analysis**

16 Independent t-tests and Chi-square analyses were performed to compare demographic
17 characteristics between participants and people who refused to participate. Imputation method
18 was used for handling missing data, which occurred in one participant in the physiotherapy
19 group for cervical movement at the 9-month follow-up due to lack of time. Two analytic
20 approaches (the last observation carried forward and likewise deletion) were applied in a
21 preliminary analysis to inform the handling of single missing data at random. Similar
22 outcomes were obtained. Missing data imputation by the last observation carried forward was
23 chosen to minimize the number of the participant eliminated from analysis. The change from
24 baseline (mean and 95% confidence interval) for each pairwise between-group comparison and
25 within groups was estimated using a linear mixed model with Bonferroni post-hoc adjustment

1 and the baseline value was used as a covariate. A partial eta squared (η^2) was calculated to
2 determine effect size. An effect size of 0.01 was regarded as small, 0.06 as medium, and 0.14
3 as large [28]. Dichotomous responder analysis was conducted to evaluate whether
4 improvement in headache frequency was clinically significant ($\geq 50\%$ reduction in the number
5 of headache days post-treatment and at follow-ups). The results are presented as relative risks
6 with 95% confidence interval.

7
8 Subgroup analyses were explored to determine whether any effects of neck treatment differed
9 according to headache diagnosis (cervicogenic or non-cervicogenic) or CMD (greater or
10 lesser). Analyses were performed based on tests for the 3-way interaction between each
11 subgroup (headache diagnosis or musculoskeletal dysfunction), treatment allocation
12 (physiotherapy and usual care), and time (11 weeks, 6 months and 9 months). No interaction
13 would indicate similar treatment effects in subgroups over time [29]. Differences in
14 demographic and baseline data between groups (cervicogenic versus non-cervicogenic, and
15 greater versus lesser CMD) were initially tested using independent-t test and chi-square.
16 Significant differences were evident in age and baseline data (headache frequency, intensity
17 and duration, and neck pain intensity and disability) between the groups. Age and baseline data
18 were then adjusted in the 3-way interaction analyses. Subgroup analyses were confined to the
19 primary outcome (headache frequency) and key secondary outcomes (headache intensity and
20 duration, and neck pain and disability).

21
22 Statistical significance was set at $p < 0.05$. Data were analyzed using SPSS Statistics version
23 18 (SPSS Co., Ltd. Bangkok, Thailand).

24
25 **Results**

1 **Participant characteristics**

2 The study commenced in January 2013 and was completed in July 2015. Figure 1 presents the
3 flow diagram of participant recruitment and retention. Sixty-five participants entered the study
4 and none were lost to follow-up for the primary outcome. Data for cervical movement was not
5 collected from one participant (3%) in the physiotherapy group at the 9-month follow-up.
6 Demographic characteristics between participants and persons who refused to join the trial are
7 presented in Table 1. Fifteen people who refused passed the preliminary screening but declined
8 diagnostic and physical assessments for headache. No significant differences in demographic
9 characteristics were found between participants and persons who refused to participate ($p >$
10 0.05)

11

12 **Interventions**

13 All participants in the physiotherapy group completed 14 treatment sessions over 10 weeks.
14 Analysis of exercise diaries indicated that participants practiced exercises on 63.4 (SD, 8.7) of
15 70 days of the treatment period. Three participants in the usual care group reported using balm
16 to reduce pain, six received massage, and one received acupuncture. Four participants in the
17 treatment group reported discomfort around their neck after the first treatment and the
18 discomfort disappeared within 24 hours. No significant adverse effects were reported in either
19 group.

20

21 **Primary outcome**

22 Descriptive data for the primary outcome from baseline to each follow period are summarized
23 in Table 2 and results of analysis of changes between and within-groups are presented in Table
24 3. The participants receiving physiotherapy had significantly reduced headache frequency
25 immediately after treatment (week 11) compared with usual care. The difference remained

1 significant at 6- and 9-month follow-ups. Effect size estimates indicated a large effect for
2 physiotherapy treatment on headache frequency (Table 4). The effectiveness of the
3 intervention was also investigated by examining the number of participants who responded to
4 treatment. At all follow up points, the physiotherapy group had a significantly higher
5 proportion of participants who experienced greater than 50% reduction in headache frequency
6 than the usual care group and 60% were headache free at 9-months (Table 5).

7

8 **Secondary outcomes**

9 Descriptive data for secondary outcomes at each time point are summarized in Table 2. Results
10 of analysis of changes between and within-groups are presented in Table 3. There were
11 significant reductions in headache intensity and duration, neck pain and disability measures
12 (VAS and NDI-TH) immediately after treatment (11 weeks), and at 6- and 9-month time points
13 compared to the usual care group. Significant differences between groups were recorded at the
14 post-treatment (11 weeks) and the 9 month follow-up, for cervical ranges of motion, quality of
15 life measures and participant's perception of treatment benefit. The exception was upper
16 cervical rotation at the 9 month follow up. There was a positive trend for reduced medication
17 use in the physiotherapy group, but differences from the usual care group were not significant.

18

19 **Subgroup analyses**

20 Descriptive data for subgroup analyses are present in Tables 6 and 7. Cervicogenic headache
21 was the most common diagnosis (69.7%, physiotherapy group; 65.6%, usual care group) and,
22 for analysis, all other headaches were pooled into a non-cervicogenic headache group.
23 Approximately 75% of participants in each group were rated with greater CMD. After
24 adjusting for age and baseline data, there were no interactions between subgroups (headache
25 diagnosis and CMD) and treatment allocation over time for the primary outcome and

1 secondary outcomes (headache intensity and duration; neck pain and disability measures ($p >$
2 0.05). The exception was headache duration, where a significant interaction was found between
3 subgroup of CMD, treatment allocation and time ($p = 0.012$). Bonferroni post-hoc results
4 showed that post-treatment (11 weeks), participants with greater CMD in the physiotherapy
5 group had significantly greater improvement in headache duration than those with lesser CMD
6 (mean difference = 3.3 hours/day, 95% CI = 0.3 to 6.3, $p = 0.031$).

7

8 **Discussion**

9 In older age, primary headaches as migraine become less typical, secondary headaches increase
10 in frequency and neck pain with headache is prevalent [2, 4, 5]. We included participants with
11 diagnoses of migraine, tension-type, mixed or cervicogenic headache. Nevertheless, our
12 primary inclusion criteria were the presence of neck pain and CMD for which there is evidence
13 of effectiveness of the physiotherapy interventions used in this study [7, 16]. This study
14 demonstrated that a treatment program consisting of cervical mobilization and therapeutic
15 exercise significantly reduced headache frequency in seniors with recurrent headache
16 compared with usual care. Greater improvement also occurred in headache intensity and
17 duration, neck pain intensity and disability, range of motion and quality of life. Participants
18 perceived treatment as beneficial. Additionally, there was a trend for reduction in average daily
19 medication dose in the physiotherapy group. Treatment effects were evident immediately after
20 treatment and were maintained in the long-term. No noteworthy adverse effects were reported.
21 Taken together, the results indicate that conservative physiotherapy management of the neck is
22 a suitable intervention for seniors with recurrent headache associated with neck pain and CMD.
23
24 Estimates of effect size were large for most headache symptoms at week 11, and at 6 and 9
25 months. In clinical terms, treating the neck was approximately twice as effective as usual care

1 in achieving a clinically relevant reduction in headache frequency (>50% reduction) and
2 approximately 60% reported complete relief from headache with neck treatment compared to
3 28% in the usual care group at the long term follow-up. Notably, two-thirds of seniors were
4 diagnosed with cervicogenic headache, and of the remainder, migraine was diagnosed most
5 commonly (60%). This may reflect our inclusion criteria of the presence of neck pain and
6 CMD and the purported greater prevalence of cervicogenic headache after the age of 50 [30,
7 31]. Additionally, with strict eligibility criteria to maintain internal validity, only one-third of
8 seniors with headache were included in the trial. Thus the trial findings may have limited
9 generalizability.

10

11 Other studies have also demonstrated effectiveness of cervical mobilization and therapeutic
12 exercise for patients with cervicogenic headache [7, 8]. Interestingly, the sub-group analyses
13 revealed that our clinical estimate of magnitude of CMD (lesser or greater) did not impact on
14 the chance of a favorable outcome and notably there was no difference in treatment effects
15 according to headache classification (cervicogenic or non-cervicogenic). We make no general
16 claim that treatment of the neck is efficacious for non-cervicogenic headaches as migraine.
17 Neck pain may be an expression of the centrally sensitized trigemino-cervical nucleus [32]
18 rather than signal a local cervical disorder. Indeed, a systematic review in 2011 concluded that
19 there was no support for the use of spinal manipulations in treatment for migraine [33].
20 Likewise, a recent study investigating the effect on migraine of medication alone or combined
21 with physiotherapy (cervical mobilization and muscle stretching) found marginal but no
22 significant additional benefit of physiotherapy on headache frequency [34].

23

24 These findings seem at variance to the results of our study where the diagnosis of migraine in
25 some participants did not mitigate against benefit from the physiotherapy intervention.

1 Interestingly in the previous migraine trial [34], there was no improvement in cervical range of
2 motion. An improvement could be expected with such treatment if any neck pain was related to
3 CMD. Our participants, receiving similar physiotherapy interventions showed improvements in
4 range of movement in excess of the minimal clinically important difference (6.5° in any
5 direction) [25] and achieved clinically meaningful change ($\geq 20\%$) in the NDI score [35]. The
6 difference in our cohort was that, regardless of headache diagnosis, they were required to have
7 CMD in association with headache and any associated neck pain. The outcomes of our trial
8 would suggest that this CMD played an active role in headache. Our results provide evidence
9 that cervicogenic headache in seniors is responsive to local treatment of the neck. The results
10 also suggest that neck pain associated with CMD could be an additional peripheral source of
11 nociception in primary headache in seniors, which is responsive to local treatment of the neck.
12 The study highlights the importance of offering a pragmatic approach for management of
13 seniors who experience recurrent headache in association with neck pain and CMD.

14
15 There are limitations to this trial. Blinding of the treating physiotherapists and participants was
16 not possible. Performance bias, that is, participants allocated to the treatment group received
17 more attention during the 10 week intervention period, may contribute to a greater chance of
18 positive outcomes. Participant selection was based on classification criteria for migraine,
19 tension-type [11] and cervicogenic headache [12], but diagnostic nerve or joint blocks to
20 confirm cervicogenic headache could not be justified for our cohort of seniors. The headache
21 diary entries were not electronically time-stamped. Some participants may have backfilled their
22 diaries, resulting in recall issues. The sample size was not justified for the subgroup analyses.
23 The subgroup analyses represented a relatively small number of participants and results should
24 be interpreted with some caution, although results were non-significant.

25

1 **Conclusions**

2 A program of low-velocity cervical mobilization and therapeutic exercise is effective for
3 seniors with recurrent headache when associated with neck pain and CMD, regardless of
4 headache classification. Given the heterogeneity of headache in this age group, concerns about
5 medication overuse and drug interactions, management of any associated painful CMD might
6 contribute positively to a multifactorial headache intervention strategy for this group.

7

8 **Conflict of Interest Statement**

9 There is no conflict of interest.

10

11

Accepted Manuscript

1 **References**

- 2 [1]. Haan J, Hollander J, Ferrari M. Migraine in the elderly: a review. *Cephalalgia*
3 2007;27:97-106.
- 4 [2]. Kelman L. Migraine changes with age: IMPACT on migraine classification. *Headache*
5 2006;46:1161-71.
- 6 [3]. Ozge A, Uluduz D, Selekler M, et al. Gender differences in older adults with chronic
7 migraine in Turkey. *Geriatr Gerontol Int* 2015;15:652-8.
- 8 [4]. Bigal ME, Liberman JN, Lipton RB. Age-dependent prevalence and clinical features of
9 migraine. *Neurology* 2006;67:246-51.
- 10 [5]. Hershey LA, Bednarczyk EM. Treatment of headache in the elderly. *Curr Treat Options*
11 *Neurol* 2013;15:56-62.
- 12 [6]. Uthaikhup S, Sterling M, Jull G. Cervical musculoskeletal impairment is common in
13 elders with headache. *Man Ther* 2009;14:636-41.
- 14 [7]. Jull G, Trott P, Potter H, et al. A randomized controlled trial of exercise and manipulative
15 therapy for cervicogenic headache. *Spine* 2002;27:1835-43.
- 16 [8]. Ylinen J, Nikander R, Nykanen M, Kautiainen H, Hakkinen A. Effect of neck exercises
17 on cervicogenic headache: a randomized controlled trial. *J Rehabil Med* 2010;42:344-9.
- 18 [9]. Braunstein D, Donnet A, Pradel V, et al. Triptans use and overuse: A
19 pharmacoepidemiology study from the French health insurance system database covering
20 4.1 million people. *Cephalalgia* 2015;35:1172-80.
- 21 [10]. Prencipe M, Casini AR, Ferrettri C, et al. Prevalence of headache in an elderly population:
22 attack frequency, disability, and use of medication. *J Neurol Neurosurg Psychiatry*
23 2001;70:377-81.
- 24 [11]. International Headache Society. The International Classification of Headache Disorders
25 2nd edition. *Cephalalgia* 2004;24 (Suppl 1):S1-151.

- 1 [12]. Sjaastad O, Fredriksen TA, Pfaffenrath V. Cervicogenic headache: Diagnostic criteria.
2 Headache 1998;38:442-5.
- 3 [13]. Jull G, Bogduk N, Marsland A. The Accuracy of Manual Diagnosis for Cervical
4 Zygapophysial Joint Pain Syndromes. Med J Aust 1988;148:233-6.
- 5 [14]. Schneider GM, Jull G, Thomas K, et al. Derivation of a clinical decision guide in the
6 diagnosis of cervical facet joint pain. Arch Phys Med Rehabil 2014;95:1695-701.
- 7 [15]. Jull G, Amiri M, Bullock-Saxton J, Darnell R, Lander C. Cervical musculoskeletal
8 impairment in frequent intermittent headache. Part 1: Subjects with single headaches.
9 Cephalalgia 2007;27:793-802.
- 10 [16]. van Etteken H, Lucas C. Efficacy of physiotherapy including a craniocervical training
11 programme for tension-type headache; a randomized clinical trial. Cephalalgia
12 2006;26:983-91.
- 13 [17]. Maitland GD, Hengeveld E, Banks K, English K. Maitland's vertebral manipulation. 6th,
14 ed. Edinburgh, New York: Butterworth-Heinemann; 2005.
- 15 [18]. Jull G, Sterling M, Falla D, Treleaven J, O'Leary S. Whiplash, headache, and neck pain.
16 Edinburgh: Churchill Livingstone; 2008.
- 17 [19]. Wegner S, Jull G, O'Leary S, Johnston V. The effect of a scapular postural correction
18 strategy on trapezius activity in patients with neck pain. Man Ther 2010;15:562-6.
- 19 [20]. Caneiro JP, O'Sullivan P, Burnett A, et al. The influence of different sitting postures on
20 head/neck posture and muscle activity. Man Ther 2010;15:54-60.
- 21 [21]. Tfelt-Hansen P, Pascual J, Ramadan N, et al. Guidelines for controlled trials of drugs in
22 migraine: third edition. A guide for investigators. Cephalalgia 2012;32:6-38.
- 23 [22]. Uthaikhup S, Paungmali A, Pirunsan U. Validation of Thai versions of the Neck
24 Disability Index and Neck Pain and Disability Scale in patients with neck pain. Spine
25 2011;36:1415-21.

- 1 [23]. Vernon H, Mior S. The Neck Disability Index: a study of reliability and validity. J
2 Manipulative Physiol Ther 1991;14:409-15.
- 3 [24]. Hall TM, Robinson KW, Fujinawa O, Akasaka K, Pyne EA. Intertester reliability and
4 diagnostic validity of the cervical flexion-rotation test. J Manipulative Physiol Ther
5 2008;31:293-300.
- 6 [25]. Audette I, Dumas JP, Cote JN, De Serres SJ. Validity and between-day reliability of the
7 cervical range of motion (CROM) device. J Orthop Sports Phys Ther 2010;40:318-23.
- 8 [26]. Lim LL, Seubsman SA, Sleigh A. Thai SF-36 health survey: tests of data quality, scaling
9 assumptions, reliability and validity in healthy men and women. Health and quality of life
10 outcomes. 2008;6:52 doi: 10.1186/1477-7525-6-52.
- 11 [27]. WHO Collaborating Centre for Drug Statistics and Methodology: Guidelines for ATC
12 classification and DDD assignment. Oslo, Norway 2013.
- 13 [28]. Cohen J. Statistical Power Analysis for the Behavioral Sciences. New York: Routledge
14 Academic; 1988.
- 15 [29]. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of
16 baseline data in clinical trials. Lancet 2000;355:1064-9.
- 17 [30]. Biondi DM, Saper JR. Geriatric headache: How to make the diagnosis and manage the
18 pain. Geriatric 2000;55:40-50.
- 19 [31]. Anthony M. Cervicogenic headache: prevalence and response to local steroid therapy.
20 Clin Exp Rheumatol 2000;18 (Suppl 19):S59-S64.
- 21 [32]. Bartsch T. Migraine and the neck: new insights from basic data. Curr Pain Headache Rep
22 2005;9:191-6.
- 23 [33]. Posadzki P, Ernst E. Spinal manipulations for the treatment of migraine: a systematic
24 review of randomized clinical trials. Cephalalgia 2011;31:964-70.

- 1 [34]. Bevilaqua-Grossi D, Goncalves MC, Carvalho GF, et al. Additional effects of a physical
2 therapy protocol on headache frequency, pressure pain threshold, and improvement
3 perception in patients with migraine and associated neck pain: a randomized clinical trial.
4 Arch Phys Med Rehabil 2015 doi: 10.1016/j.apmr.2015.12.006.
- 5 [35]. Young BA, Walker MJ, Strunce JB, Boyles RE, Whitman JM, Childs JD.
6 Responsiveness of the Neck Disability Index in patients with mechanical neck disorders.
7 Spine J 2009;9:802-8.

8
9
Accepted Manuscript

Figure 1 Flow diagram of the trial

Accepted Manuscript

Table 1 Demographic characteristics between participants and persons who refused to participate

Variables	Participants			Refusers (n =24)	p-value**
	Physiotherapy (n = 33)	Usual care (n = 32)	Total (n =65)		
Age (yrs), mean (SEM)	59.9 (1.2)	61.6 (0.9)	60.7 (0.7)	63.2 (1.4)	0.10
Gender (female), %	81.8	90.6	86.2	87.5	0.87
BMI (kg/m ²), mean (SEM)	24.1 (0.7)	25.8 (0.6)	24.9 (0.5)	26.6 (0.9)*	0.22
Employment status, n					
Retired	7	8		-	-
Full time employment	9	3		-	-
Self-employed	10	16		-	-
Housewife	7	5		-	-
History of headache (yrs), mean (SEM)	8.5 (1.6)	6.3 (1.5)	7.4 (1.1)	3.9 (1.1)	0.07
Headache diagnosis (type), n					0.58
Migraine	6	7	13	1*	
Tension-type headache	2	0	2	0	
Cervicogenic headache	23	21	44	8*	
Mixed headache	2	4	6	0	
CMD (greater), %	75.8	75.0	75.4	55.6*	0.21

CMD = cervical musculoskeletal impairment

* Total number of refusers (n = 9)

** Compared between refusers and total participants

Table 2 Primary and secondary outcomes for each intervention group. Means and (standard deviations) are presented.

Outcome variables	Physiotherapy (n = 33)				Usual care (n = 32)			
	Baseline	11 weeks	6 months	9 months	Baseline	11 weeks	6 months	9 months
Primary outcome								
Headache frequency (days/week)	4.3 (0.4)	1.7 (0.4)	1.5 (0.4)	0.8 (0.2)	3.9 (0.4)	3.0 (0.4)	2.9 (0.5)	2.9 (0.5)
Secondary outcome								
Headache intensity (0-10 NRS)	4.5 (0.3)	1.4 (0.3)	1.5 (0.3)	1.2 (0.3)	4.7 (0.4)	4.8 (0.4)	4.0 (0.5)	3.6 (0.6)
Headache duration (hours/day)	5.2 (1.0)	2.2 (0.6)	2.7 (0.9)	1.9 (0.9)	4.8 (1.0)	4.7 (1.0)	4.7 (1.1)	5.60 (1.2)
Neck pain intensity (0-10 VAS)	5.1 (0.3)	1.7 (0.2)	1.4 (0.3)	1.5 (0.3)	5.4 (0.2)	4.73 (0.2)	4.8 (0.3)	4.80 (0.3)
Neck pain and disability (%)	30.9 (1.6)	10.1 (1.2)	9.2 (1.3)	8.4 (1.3)	27.7 (1.7)	26.4 (1.5)	24.6 (1.6)	23.83 (1.8)
Cervical range of motion (degrees)								
Flexion-extension	105.0 (1.6)	115.6 (1.9)	N/A	113.0 (1.7)	105.5 (1.8)	105.9 (1.6)	N/A	107.23 (2.5)
Lateral flexion (right-left)	58.5 (2.0)	66.3 (2.1)	N/A	68.1 (2.1)	59.7 (1.6)	59.9 (1.5)	N/A	64.6 (1.7)

Outcome variables	Physiotherapy (n = 33)				Usual care (n = 32)			
	Baseline	11 weeks	6 months	9 months	Baseline	11 weeks	6 months	9 months
Rotation (right-left)	115.2 (2.2)	125.0 (1.9)	N/A	125.2 (2.1)	115.1 (2.0)	115.5 (2.4)	N/A	117.9 (1.9)
Upper cervical rotation	47.7 (1.1)	53.3 (1.0)	N/A	53.6 (1.2)	49.0 (0.9)	51.0 (1.0)	N/A	51.7 (1.0)
Quality of life SF 36 (%)								
Physical component summary	54.5 (2.6)	78.4 (2.0)	N/A	77.7 (2.1)	55.7 (2.8)	53.6 (2.7)	N/A	56.6 (2.2)
Mental component summary	65.6 (2.8)	83.7 (1.9)	N/A	79.4 (2.4)	68.8 (2.7)	62.1 (3.0)	N/A	63.2 (3.0)
Treatment benefit (0-10 VAS)	4.5 (0.6)	9.3 (0.2)	N/A	9.4 (0.2)	3.6 (0.6)	6.3 (0.5)	N/A	6.7 (0.4)
Medication (DDD per week)	2.0 (1.5)	0.04 (0.02)	0.05 (0.04)	0.03 (0.02)	0.7 (0.3)	1.2 (0.8)	1.0 (0.8)	1.3 (0.8)

Data are expressed in mean (standard error), NRS = Numerical Rating Scale, VAS = Visual Analogue Scale, DDD = Defined Daily Dose

Table 3 Means (standard error) for within group changes and adjusted mean (95% confidence interval) for differences in between-group change for all outcome variables

Outcome variables	Time frame	Change within groups*				Changes between-groups**	
		Physiotherapy	p-value	Usual care	p-value	Difference	p-value
Primary outcome							
Headache frequency (days/week)	Baseline-week 11	2.6 (0.3)	<0.001	0.9 (0.4)	0.052	-1.6 (-2.5 to -0.6)	0.001
	Baseline-6 months	2.8 (0.4)	<0.001	1.0 (0.4)	0.041	-1.7 (-2.6 to -0.8)	0.001
	Baseline-9 months	3.5 (0.3)	<0.001	1.0 (0.3)	0.023	-2.4 (-3.2 to -1.5)	<0.001
Secondary outcomes							
Headache intensity (0-10 NRS)	Baseline-week 11	3.1 (0.3)	<0.001	-0.1 (0.3)	1.00	-3.3 (-4.1 to -2.4)	<0.001
	Baseline-6 months	2.9 (0.4)	<0.001	0.7 (0.4)	0.49	-2.3 (-3.4 to -1.3)	<0.001
	Baseline-9 months	3.2 (0.5)	<0.001	1.1 (0.5)	0.32	-2.4 (-3.6 to -1.1)	<0.001
Headache duration (hours/day)	Baseline-week 11	3.0 (0.8)	0.005	0.2 (0.9)	1.00	-2.6 (-4.4 to -0.7)	0.007
	Baseline-6 months	2.5 (0.8)	0.020	0.2 (0.8)	1.00	-2.2 (-4.4 to -0.04)	0.046
	Baseline-9 months	3.3 (1.2)	0.033	-0.8 (1.2)	1.00	-3.8 (-6.6 to -1.0)	0.008

Outcome variables	Time frame	Change within groups*				Changes between-groups**	
		Physiotherapy	p-value	Usual care	p-value	Difference	p-value
Neck pain intensity (0-10 VAS)	Baseline-week 11	3.5 (0.3)	<0.001	0.7 (0.3)	0.18	-3.0 (-3.7 to -2.4)	<0.001
	Baseline-6 months	3.7 (0.3)	<0.001	0.6 (0.3)	0.58	-3.3 (-4.1 to -2.6)	<0.001
	Baseline-9 months	3.7 (0.3)	<0.001	0.6 (0.3)	0.59	-3.3 (-4.1 to -2.4)	<0.001
Neck pain and disability (%)	Baseline-week 11	20.8 (1.5)	<0.001	1.3 (1.5)	1.00	-17.7 (-21.1 to -14.2)	<0.001
	Baseline-6 months	21.7 (1.7)	<0.001	3.1 (1.7)	0.49	-16.5 (-20.4 to -12.6)	<0.001
	Baseline-9 months	22.5 (1.8)	<0.001	3.9 (1.9)	0.26	-16.4 (-20.6 to -12.2)	<0.001
Cervical range of motion							
(degrees)							
Flexion-extension	Baseline-week 11	-10.6 (1.5)	<0.001	-0.5 (1.6)	1.00	10.0 (6.0 to 14.0)	<0.001
	Baseline-9 months	-8.1 (1.7)	<0.001	-1.8 (1.7)	0.91	6.19 (1.5 to 10.9)	0.010
Lateral flexion (right-left)	Baseline-week 11	-7.9 (1.6)	<0.001	-0.3 (1.7)	1.00	7.1 (3.0 to 11.3)	0.001
	Baseline-9 months	-9.6 (1.6)	<0.001	-4.9 (1.6)	0.01	4.3 (0.2 to 8.5)	0.043
Rotation (right-left)	Baseline-week 11	-9.8 (1.8)	<0.001	-0.3 (1.8)	1.00	9.5 (4.8 to 14.2)	<0.001
	Baseline-9 months	-10.0 (1.9)	<0.001	-2.8 (1.9)	0.48	7.3 (2.6 to 12.0)	0.003

Outcome variables	Time frame	Change within groups*				Changes between-groups**	
		Physiotherapy	p-value	Usual care	p-value	Difference	p-value
Upper cervical rotation	Baseline-week 11	-5.6 (1.2)	<0.001	-1.9 (1.2)	0.30	2.8 (0.1 to 5.5)	0.045
	Baseline-9 months	-5.9 (1.2)	<0.001	-2.7 (1.2)	0.10	2.4 (-0.6 to 5.4)	0.11
Quality of life SF 36 (%)							
Physical component summary	Baseline-week 11	-24.0 (2.7)	<0.001	2.1 (2.7)	1.00	25.3 (19.2 to 31.4)	<0.001
	Baseline-9 months	-23.3 (2.6)	<0.001	-0.9 (2.7)	1.00	21.6 (16.0 to 27.2)	<0.001
Mental component summary	Baseline-week 11	-18.1 (2.3)	<0.001	6.7 (2.4)	0.019	23.4 (17.6 to 29.2)	<0.001
	Baseline-9 months	-13.8 (2.5)	<0.001	5.6 (2.6)	0.10	17.9 (11.6 to 24.2)	<0.001
Treatment benefit (0-10 VAS)	Baseline-week 11	-4.8 (0.7)	<0.001	-2.8 (0.7)	0.001	3.1 (2.1 to 4.1)	<0.001
	Baseline-9 months	-4.9 (0.7)	<0.001	-3.1 (0.7)	<0.001	2.8 (2.0 to 3.6)	<0.001
Medication (DDD per week)	Baseline-week 11	2.0 (1.1)	0.56	-0.5 (1.2)	1.00	-1.3 (-2.8 to 0.3)	0.10
	Baseline-6 months	1.9 (1.2)	0.57	-0.3 (1.2)	1.00	-1.1 (-2.6 to 0.5)	0.17
	Baseline-9 months	2.0 (1.2)	0.56	-0.6 (1.2)	1.00	-1.4 (-3.0 to 0.1)	0.073

** adjusted for baseline values

* For changes within groups, positive values denote improvement, except for cervical range of motion, SF 36 and treatment benefit where negative values denote improvement.

** For differences in changes between-groups, positive values in cervical range of motion, SF 36 and treatment benefit, and negative values in the headache characteristics, neck pain intensity, neck disability and medication favor the first named group (physiotherapy) in the pairwise comparison.

Table 4 Effect size estimates for group differences

Outcome	Effect size (η^2p)		
	Baseline to after treatment	Baseline to 6 month- follow up	Baseline to 9 month- follow up
Headache frequency	0.16	0.17	0.35
Headache intensity	0.49	0.25	0.19
Headache duration	0.11	0.06	0.11

Accepted Manuscript

Table 5 The number of participants (%) with a greater than 50% and 100% reduction in headache frequency at follow-ups compared to baseline

Headache frequency	50% reduction		p-value	Relative risk (95% confidence interval)	100% reduction		p-value	Relative risk (95% confidence interval)
	Physiotherapy n =33	Usual care n =32			Physiotherapy n =33	Usual care n =32		
11 weeks	24 (72.7)	13 (40.6)	0.009	1.8 (1.1 to 2.9)	16 (48.5)	2 (6.3)	<0.001	7.8 (1.9 to 31.1)
6 months	27 (81.8)	15 (46.9)	0.003	1.8 (1.2 to 2.6)	15 (45.5)	7 (21.7)	0.045	2.1 (1.0 to 4.4)
9 months	31 (93.9)	14 (43.8)	<0.001	2.2 (1.4 to 3.2)	20 (60.6)	9 (28.1)	0.008	2.2 (1.2 to 4.0)

Table 6 Sub-group analyses based on cervicogenic or non-cervicogenic headache for the primary outcome and key secondary outcomes

Outcome variables	Physiotherapy		Usual care		p value for interaction treatment*sub-group* time
	Cervicogenic (n = 23)	Non-cervicogenic (n = 10)	Cervicogenic (n = 21)	Non-cervicogenic (n = 11)	
Primary outcome					
Headache frequency (days/week)	1.6 (0.6 to 2.5)	1.6 (0.3 to 3.0)	2.1 (1.0 to 3.1)	4.0 (2.8 to 5.2)	0.19
Secondary outcome					
Headache intensity (0-10 NRS)	2.1 (1.1 to 3.0)	1.5 (0.2 to 2.9)	3.7 (2.6 to 4.7)	4.7 (3.4 to 5.9)	0.079
Headache duration (hours/day)	3.4 (1.3 to 5.5)	0.6 (-2.4 to 3.6)	4.2 (1.8 to 6.6)	6.5 (3.7 to 9.3)	0.87
Neck pain intensity (0-10 VAS)	1.8 (1.3 to 2.3)	1.1 (0.3 to 1.8)	4.6 (4.0 to 5.1)	5.1 (4.4 to 5.9)	0.45
Neck pain and disability (%)	10.2 (7.8 to 12.7)	4.6 (1.0 to 8.3)	25.0 (22.4 to 27.6)	27.0 (23.5 to 30.5)	0.23

Value are estimated mean (95% confidence interval) after adjusting for baseline values and age

Table 7 Sub-group analyses based on greater or lesser musculoskeletal dysfunction for the primary outcome and key secondary outcomes

Outcome variables	Physiotherapy		Usual care		p value for interaction treatment*sub-group* time
	Greater dysfunction (n = 25)	Lesser dysfunction (n = 8)	Greater dysfunction (n = 24)	Lesser dysfunction (n = 8)	
Primary outcome					
Headache frequency (days/week)	1.1 (0.5 to 1.7)	1.2 (0.2 to 2.2)	3.1 (2.5 to 3.6)	3.1 (2.1 to 4.2)	0.15
Secondary outcome					
Headache intensity (0-10 NRS)	1.2 (0.6 to 1.8)	2.0 (0.9 to 3.1)	3.9 (3.3 to 4.5)	4.7 (3.6 to 5.7)	0.20
Headache duration (hours/day)	1.9 (0.4 to 3.4)	2.7 (0.01 to 5.3)	4.9 (3.4 to 6.4)	6.0 (3.3 to 8.7)	0.012
Neck pain intensity (0-10 VAS)	1.6 (1.1 to 2.1)	1.3 (0.5 to 2.2)	4.5 (4.0 to 5.0)	5.5 (4.6 to 6.4)	0.68
Neck pain and disability (%)	8.1 (5.6 to 10.5)	9.6 (5.3 to 13.8)	24.9 (22.5 to 27.3)	28.5 (24.1 to 32.9)	0.71

Value are estimated mean (95% confidence interval) after adjusting for baseline values and age

Accepted Manuscript